Jonathan D. (Jon) Campbell, MS, PhD, is the Chief Science Officer (CSO) of the National Pharmaceutical Council (NPC), which sponsors and conducts research on health policy issues related to the development and use of innovative biopharmaceuticals to improve the health of patients. NPC’s research contributes to the body of evidence that supports discussions and decisions about patient access to treatments, appropriate use, and the value that innovative treatments provide to both patients and the healthcare system. As CSO, Dr. Campbell leads NPC’s research agenda in concert with NPC’s board and research team. As a researcher and advocate for improving the U.S. healthcare system through sustainable access and biopharmaceutical innovation, Dr. Campbell is dedicated to conducting research that helps decision- makers understand the tradeoffs and consequences of health policies that impact patient access to treatments and the ecosystem of biopharmaceutical innovation. Dr. Campbell shaped his career within academics. After training at the University of Washington, he joined the faculty at the University of Colorado Anschutz Medical Campus, earning multiple appointments in Pharmacy and Public Health from 2009 to 2020. During his academic career, Dr. Campbell gained insights on the work of biopharmaceutical manufacturers through a summer internship at Novartis in Basel, Switzerland (2004) and expanded his research and training network through a sabbatical in Budapest, Hungary with Syreon Research Institute (2018). Prior to joining NPC, Dr. Campbell served as Senior Vice President for Health Economics at the Institute for Clinical and Economic Review (ICER), where he made contributions to ICER assessments and their value assessment methodology. Dr. Campbell is an author of over 250 manuscripts and abstracts in the field of health policy research and value assessment and holds an adjunct faculty appointment within the Center for Evaluation of Value and Risk in Health at Tufts University School of Medicine. Dr. Campbell is passionate about mentoring others and enjoys supporting individuals working to deepen their expertise in the health economics and outcomes research field. Dr. Campbell’s training includes graduate degrees in pharmaceutical outcomes research (PhD) and biostatistics (MS) from the University of Washington. He graduated Phi Beta Kappa with Bachelor of Arts degrees in mathematics and chemistry from St. Olaf College.